CR20210514A - USO DE REBOXETINA PARA EL TRATAMIENTO DE NARCOLEPSIA (Divisional 2021-0183) - Google Patents
USO DE REBOXETINA PARA EL TRATAMIENTO DE NARCOLEPSIA (Divisional 2021-0183)Info
- Publication number
- CR20210514A CR20210514A CR20210514A CR20210514A CR20210514A CR 20210514 A CR20210514 A CR 20210514A CR 20210514 A CR20210514 A CR 20210514A CR 20210514 A CR20210514 A CR 20210514A CR 20210514 A CR20210514 A CR 20210514A
- Authority
- CR
- Costa Rica
- Prior art keywords
- reboxetine
- narcolepsy
- treat narcolepsy
- cataplexy
- treat
- Prior art date
Links
- 201000003631 narcolepsy Diseases 0.000 title abstract 4
- CBQGYUDMJHNJBX-RTBURBONSA-N reboxetine Chemical compound CCOC1=CC=CC=C1O[C@H](C=1C=CC=CC=1)[C@@H]1OCCNC1 CBQGYUDMJHNJBX-RTBURBONSA-N 0.000 title abstract 4
- 229960003770 reboxetine Drugs 0.000 title abstract 4
- 208000023046 narcolepsy-cataplexy syndrome Diseases 0.000 abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Anesthesiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
En la presente se describen métodos para el tratamiento de narcolepsia con cataplexia, que comprenden la administración de reboxetina a un ser humano que lo necesita. La reboxetina también se puede usar en la elaboración de un medicamento para el tratamiento de la narcolepsia con cataplexia. También se describen en el presente documento kits que comprenden una composición farmacéutica que comprende reboxetina e instrucciones para usar la composición farmacéutica para tratar la narcolepsia con cataplexia en un ser humano.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862745956P | 2018-10-15 | 2018-10-15 | |
| PCT/US2019/056134 WO2020081461A1 (en) | 2018-10-15 | 2019-10-14 | Use of reboxetine to treat narcolepsy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20210514A true CR20210514A (es) | 2021-11-12 |
Family
ID=70284075
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20210514A CR20210514A (es) | 2018-10-15 | 2019-10-14 | USO DE REBOXETINA PARA EL TRATAMIENTO DE NARCOLEPSIA (Divisional 2021-0183) |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP3866768A4 (es) |
| JP (2) | JP2022504975A (es) |
| KR (2) | KR20210071046A (es) |
| CN (1) | CN112888430A (es) |
| AU (3) | AU2019361915A1 (es) |
| BR (1) | BR112021007019A2 (es) |
| CL (1) | CL2021000924A1 (es) |
| CO (1) | CO2021004681A2 (es) |
| CR (1) | CR20210514A (es) |
| EC (1) | ECSP21031200A (es) |
| IL (2) | IL319177A (es) |
| MX (2) | MX2021004207A (es) |
| PE (1) | PE20211199A1 (es) |
| SG (1) | SG11202103588WA (es) |
| WO (1) | WO2020081461A1 (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019245975A1 (en) | 2018-06-17 | 2019-12-26 | Axsome Therapeutics, Inc. | Compositions for delivery of reboxetine |
| US20200147093A1 (en) | 2018-10-15 | 2020-05-14 | Axsome Therapeutics, Inc. | Use of esreboxetine to treat nervous system disorders such as fibromyalgia |
| US11020402B2 (en) | 2018-10-15 | 2021-06-01 | Axsome Therapeutics, Inc. | Use of reboxetine to treat narcolepsy |
| CR20220247A (es) * | 2019-12-03 | 2022-08-18 | Axsome Therapeutics Inc | Uso de reboxetina para tratar los trastornos del sistema nervioso |
| US12616702B2 (en) | 2019-12-03 | 2026-05-05 | Axsome Therapeutics, Inc. | Use of reboxetine to treat narcolepsy |
| KR102893312B1 (ko) * | 2021-10-19 | 2025-12-01 | 단국대학교 천안캠퍼스 산학협력단 | 레복세틴을 유효성분으로 포함하는 근감소증의 예방 또는 치료용 조성물 |
| WO2025207664A1 (en) * | 2024-03-25 | 2025-10-02 | Axsome Therapeutics, Inc. | Use of reboxetine to treat narcolepsy |
| US20260176242A1 (en) * | 2024-12-23 | 2026-06-25 | Axsome Therapeutics, Inc. | 2-((2-ethoxyphenoxy)(phenyl)methyl)-4-nitrosomorpholine |
| US12565478B1 (en) | 2025-01-21 | 2026-03-03 | Axsome Therapeutics, Inc. | (S)-2-((S)-(2-ethoxyphenoxy)(phenyl)methyl)-4-nitrosomorpholine |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6485746B1 (en) * | 2000-08-25 | 2002-11-26 | Neurocrine Biosciences, Inc. | Controlled-release sedative-hypnotic compositions and methods related thereto |
| MXPA04006163A (es) * | 2001-12-20 | 2004-11-01 | Pharmacia Corp | Formas de dosis de liberacion sostenida del orden-cero y metodo de fabricacion de las mismas. |
| MY136318A (en) * | 2002-07-25 | 2008-09-30 | Pharmacia Corp | Sustained-release tablet composition |
| BRPI0511941A (pt) * | 2004-06-09 | 2008-01-22 | Pfizer | uso de (s, s)-reboxetina ou reboxetina racêmica |
| RU2019114940A (ru) * | 2013-03-13 | 2019-06-28 | ЭРИЭЛ БАЙОФАРМА, ЭлЭлСи | Лечение катаплексии |
-
2019
- 2019-10-14 BR BR112021007019-2A patent/BR112021007019A2/pt unknown
- 2019-10-14 SG SG11202103588WA patent/SG11202103588WA/en unknown
- 2019-10-14 WO PCT/US2019/056134 patent/WO2020081461A1/en not_active Ceased
- 2019-10-14 IL IL319177A patent/IL319177A/en unknown
- 2019-10-14 IL IL282311A patent/IL282311B2/en unknown
- 2019-10-14 EP EP19874099.5A patent/EP3866768A4/en active Pending
- 2019-10-14 MX MX2021004207A patent/MX2021004207A/es unknown
- 2019-10-14 KR KR1020217013455A patent/KR20210071046A/ko not_active Ceased
- 2019-10-14 PE PE2021000514A patent/PE20211199A1/es unknown
- 2019-10-14 KR KR1020247025741A patent/KR20240119194A/ko active Pending
- 2019-10-14 CR CR20210514A patent/CR20210514A/es unknown
- 2019-10-14 JP JP2021520615A patent/JP2022504975A/ja active Pending
- 2019-10-14 AU AU2019361915A patent/AU2019361915A1/en not_active Abandoned
- 2019-10-14 CN CN201980067756.9A patent/CN112888430A/zh active Pending
-
2021
- 2021-04-12 MX MX2025003477A patent/MX2025003477A/es unknown
- 2021-04-14 CO CONC2021/0004681A patent/CO2021004681A2/es unknown
- 2021-04-14 CL CL2021000924A patent/CL2021000924A1/es unknown
- 2021-04-30 EC ECSENADI202131200A patent/ECSP21031200A/es unknown
-
2023
- 2023-02-16 AU AU2023200917A patent/AU2023200917A1/en not_active Abandoned
-
2025
- 2025-02-23 AU AU2025201286A patent/AU2025201286A1/en active Pending
- 2025-06-10 JP JP2025096479A patent/JP2025134749A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020081461A1 (en) | 2020-04-23 |
| CA3115983A1 (en) | 2020-04-23 |
| IL319177A (en) | 2025-04-01 |
| NZ775057A (en) | 2024-09-27 |
| CL2021000924A1 (es) | 2021-09-03 |
| CO2021004681A2 (es) | 2021-06-21 |
| AU2023200917A1 (en) | 2023-03-23 |
| IL282311B1 (en) | 2025-04-01 |
| SG11202103588WA (en) | 2021-05-28 |
| MX2021004207A (es) | 2021-08-11 |
| MX2025003477A (es) | 2025-05-02 |
| AU2019361915A1 (en) | 2021-05-13 |
| KR20210071046A (ko) | 2021-06-15 |
| IL282311B2 (en) | 2025-08-01 |
| EP3866768A1 (en) | 2021-08-25 |
| JP2022504975A (ja) | 2022-01-13 |
| IL282311A (en) | 2021-05-31 |
| CN112888430A (zh) | 2021-06-01 |
| PE20211199A1 (es) | 2021-07-01 |
| BR112021007019A2 (pt) | 2021-07-13 |
| JP2025134749A (ja) | 2025-09-17 |
| ECSP21031200A (es) | 2021-05-31 |
| EP3866768A4 (en) | 2022-01-05 |
| KR20240119194A (ko) | 2024-08-06 |
| AU2025201286A1 (en) | 2025-03-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2021000924A1 (es) | Uso de reboxetina para el tratamiento de narcolepsia | |
| CL2023001949A1 (es) | Anticuerpos que se dirigen al gp120 de vih y métodos de uso (divisional de solicitud de patente no. 3422-2020) | |
| CL2022001743A1 (es) | Dosis de gamma-hidroxibutirato (ghb) | |
| CL2025001913A1 (es) | Anticuerpo anti-nectina-4; conjugado que lo comprende; composición farmacéutica; y su uso. | |
| MX2019010757A (es) | Métodos y composiciones relacionados con el tratamiento combinado con antiinflamatorios y nanoportadores sintéticos que comprenden un inmunosupresor. | |
| GT201700246A (es) | Métodos y kits para tratar la depresión | |
| CL2008001268A1 (es) | Compuestos derivados de n-[6-amino-5-aril-piridin-2-il]-carboxamida; composicion farmaceutica que los comprende; composicion farmaceutica combinada que los comprende junto a otro agente farmacologico adicional; y uso de los mismos en el tratamiento del dolor. | |
| MX2022010357A (es) | Anticuerpos inhibidores de anti-pcsk9 para el tratamiento de pacientes con hiperlipidemia que se someten aferesis de lipoproteina. | |
| AR101312A1 (es) | Combinaciones de inhibidores de bet e inhibidores de tirosina quinasa de bruton | |
| MX2019003134A (es) | Terapia de combinacion. | |
| MX2018016332A (es) | Quimioterapias de combinacion. | |
| MX2020004513A (es) | Cocristales, composiciones farmacéuticas de los mismos y métodos de tratamiento que los implican. | |
| MX2016015437A (es) | Combinacion que comprende un glucocorticoide y edo-s101. | |
| CL2019002218A1 (es) | Formulaciones de combinación triple y métodos para tratar o reducir el riesgo de enfermedad cardiovascular. | |
| MX2021003263A (es) | Combinacion de un antagonista de proteina de muerte programada 1 (pd-1), un inhibidor de ataxia telangiectasia y proteina relacionada con rad3 (atr) y un agente de platino para el tratamiento de cancer. | |
| CL2019001918A1 (es) | Métodos para tratar infecciones bacterianas. | |
| MX2024003918A (es) | Agente terapeutico que induce citotoxicidad para usarse en terapia del cancer. | |
| MX2016011025A (es) | Composiciones de grapiprant y metodos para usar las mismas. | |
| MX2024012392A (es) | Terapia combinada para el tratamiento del cancer | |
| MX2022014577A (es) | Gel intestinal de levodopa y carbidopa y metodos de uso. | |
| MX2017009325A (es) | Gel intestinal de levodopa y carbidopa y metodos de uso. | |
| CL2021003442A1 (es) | Composición farmacéutica que comprende idelalisib y defactinib; y métodos para el tratamiento de cáncer. | |
| MX2021011334A (es) | Anticuerpos que tienen especificidad para btn2 y usos de los mismos. | |
| CO2023000194A2 (es) | Administración de sulcardina para el tratamiento de fibrilación auricular aguda | |
| CL2022001476A1 (es) | Uso de reboxetina para tratar los trastornos del sistema nervioso |